Liminatus Pharma, Inc. Class A Common Stock (LIMN) vs Xenetic Biosciences, Inc. (XBIO)

A side-by-side comparison of Liminatus Pharma, Inc. Class A Common Stock and Xenetic Biosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Liminatus Pharma, Inc. Class A Common Stock logo
LIMN
Liminatus Pharma, Inc. Class A Common Stock
$5M
$3.70HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Xenetic Biosciences, Inc. logo
XBIO
Xenetic Biosciences, Inc.
$5M
$2.12HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — LIMN vs XBIO

growth of $100 · dividends reinvested · last 1y
LIMN -98.4% (-98.4%/yr)XBIO -18.5% (-18.5%/yr)XBIO compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $1002026$2$81
LIMN XBIO

LIMN vs XBIO: by the numbers

  • •LIMN is the larger company ($5M vs $5M market cap).
  • •Both run net losses; LIMN's is the smaller (0.00% vs -75.90% net margin).

Metrics side by side

Valuation

MetricLIMNXBIO
P/S ratioN/A1.49
P/B ratio16.530.80

Profitability

MetricLIMNXBIO
Gross margin0.00%100.00%
Operating margin0.00%-95.23%
Net margin0.00%-75.90%
ROE-4165.92%-40.76%
ROIC-225.12%-43.50%

Growth (annualized)

MetricLIMNXBIO
Revenue CAGR (5Y)N/A34.31%
Total return CAGR (5Y)N/A-34.54%

Go deeper

Full LIMN analysisFull XBIO analysisInteractive comparison tool

Dig into the metrics

Liminatus Pharma, Inc. Class A Common Stock ROEXenetic Biosciences ROELiminatus Pharma, Inc. Class A Common Stock operating marginXenetic Biosciences operating marginLiminatus Pharma, Inc. Class A Common Stock revenue growthXenetic Biosciences revenue growthLiminatus Pharma, Inc. Class A Common Stock free cash flowXenetic Biosciences free cash flow

Liminatus Pharma, Inc. Class A Common Stock & Xenetic Biosciences appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.